Therapeutic solutions for neurodegeneration
There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.
AlzProtect designs and develops innovative therapeutic solutions for these diseases.
Our objective: to slow down or stop neurodegeneration and, where possible, to restore some brain capacities
An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.
Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.
News
AlzProtect obtains authorization to start a Phase 2a clinical trial in PSP
AlzProtect today announced that the ANSM has authorized the launch of a phase 2a clinical trial with the drug candidate AZP2006 in the indication of Progressive Supranuclear Paralysis (PSP).